To the Editor: Dermatomyositis causes significant morbidity and mortality and the increased risk of progressive interstitial lung disease and internal malignancy requires physicians to monitor these patients closely. 1 However, multiple diagnostic and classification criteria for dermatomyositis and other inflammatory myopathies consistently miss a large number of patients. 1 This has led to many patients receiving the diagnosis of lupus or undifferentiated connective tissue disease (UCTD), which has served as a sort of wastebasket for patients presenting with autoimmune and rheumatologic complaints but not meeting the criteria for any specific condition. 2 The goal of this retrospective chart review was to evaluate those in our large database cohort with dermatomyositis who were not initially diagnosed and to advocate for increasing the suspicion for dermatomyositis among physicians making a new diagnosis of UCTD.
Characteristics of the study population are presented in Table I . Of the 232 confirmed dermatomyositis cases, 103 were diagnosed before presentation at Penn (44.4%). Nearly 67% of the undiagnosed cases were labeled as lupus or UCTD (Fig 1) . Of the undiagnosed, 43% were seen by dermatology, 31% by rheumatology, 4% by other, and 22% were unknown (we did not have a record of the original encounter). The delay between original presentation and final diagnosis ranged from 2.2 weeks to 267 months with a median of 15.5 months. This lag is of tremendous clinical significance because the increased malignancy risk is highest in the first 1-2 years after symptom onset. 3 In the subset of clinically amyopathic dermatomyositis patients, 80 of 112 (71.4%) had a different diagnosis compared with 49 of 120 (40.8%) in the classic dermatomyositis group (P \ .00001). The median delay was 17.1 months for amyopathic dermatomyositis compared with 12.2 months in classic dermatomyositis patients (not significant). Our results in the clinically amyopathic dermatomyositis group, which includes amyopathic as well as hypomyopathic patients, provides further evidence that patients without muscle disease are at even higher risk for receiving a misdiagnosis.
Of the 232 cases, 27 did not have documentation of the specific type of rash at diagnosis. However, in the remaining 205 cases, 86% had Gottron sign or papules. The 92.6% of patients who did not have Gottron's sign had $1 of the following findings on skin exam: V sign; shawl sign; holster sign; heliotrope; mechanics hands; and periungual telangiectasia, erythema, or dystrophy. The greatly improved EULAR-ACR (European League Against Rheumatism-American College of Rheumatology) criteria for idiopathic inflammatory myopathies include only heliotrope, Gottron sign, or Gottron papules. 1, 4 The prevalence of skin biopsy was 62% in the originally diagnosed group and 66% in the misdiagnosed category. Of those biopsied in the misdiagnosed group (includes both biopsies performed at our institution and outside as long as the report was available), 82% showed interface dermatitis and 7% showed increased mucin.
Studies on UCTD, which has been defined as signs and symptoms suggestive of a connective tissue disease but not fulfilling the criteria for any of the defined connective tissue diseases, have shown that as diagnostic/classification criteria become more sensitive more of these patients can be diagnosed with a distinct connective tissue disease. 5 We hope to raise awareness that patients labeled with UCTD might have dermatomyositis. Collaborative efforts to refine the criteria for a diagnosis of dermatomyositis are needed.
Limitations of this study include that patients reflect the population of only one institution. Thus, the results might not be generalizable to other settings. Because this is a retrospective chart review, results are also limited by missing data and nonstandardized physical examinations and laboratory data across patients and physicians. In vitro assessment of the broad-spectrum ultraviolet protection of clothing
To the Editor: Although ultraviolet (UV) B is a well known carcinogen, recent evidence suggests that UVA also contributes to skin cancer risk. 1 To promote protection against UVA, the Food and Drug Administration standardized labeling and effectiveness testing for over-the-counter sunscreens in 2011; while maintaining the in vivo testing for evaluating UVB protection, this criterion added an in vitro measurement for UVA protection. Originally suggested by Diffey et al, 2 the test calculates the wavelength at which the integral of the UV spectral absorbance curve reaches 90% of the total integral 290-400 nm. A critical wavelength (CW) minimum of 370 nm defines broadspectrum coverage.
Currently, there is no standard to measure UVA protection in clothing. However, there are voluntary standards to label clothing as UV protective with an ultraviolet protective factor (UPF), 3, 4 which is an in vitro test that primarily assesses protection against UVB. 5 No current labeling standard measures UVA protection.
To address this shortcoming, we performed a proof-of-concept study examining UVA protection afforded by common clothing garments using the Diffey critical wavelength method. 2 We compared the broadspectrum UV protection between regular clothing fabrics (t-shirts and jeans, Breakdown of prior diagnoses in dermatomyositis patients. *Undiagnosed were cases in which physician evaluation was obtained, however, no prior diagnosis was indicated. Includes patients who were told that their diagnosis was not known.
y Diagnoses included dermatitis (n ¼ 7), rosacea (n ¼ 5), eczema (n ¼ 5), psoriasis (n ¼ 4), rheumatoid arthritis (n ¼ 2), mixed connective tissue disease (n ¼ 2), lichen planus (n ¼ 1), juvenile inflammatory arthritis (n ¼ 1), chronic urticaria (n ¼ 1), fibromyalgia (n ¼ 1), inclusion body myositis (n ¼ 1), vasculitis (n ¼ 1), serum sickness (n ¼ 1), and polymyalgia rheumatica (n ¼ 1). CLE, Cutaneous lupus erythematosus; DM, dermatomyositis; SLE, systemic lupus erythematosis; UCTD, undifferentiated connective tissue disease.
